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Background: The traditional smallpox vaccine, administered by scarification, was discontinued in the general
population from 1980, because of the absence of new smallpox cases. However, the development of an effective
prophylactic vaccine against smallpox is still necessary, to protect from the threat of deliberate release of the variola
virus for bioterrorism and from new zoonotic infections, and to improve the safety of the traditional vaccine.
Preventive vaccination still remains the most effective control and new vectors have been developed to generate
recombinant vaccines against smallpox that induce the same immunogenicity as the traditional one. As protective
antibodies are mainly directed against the surface proteins of the two infectious forms of vaccinia, the intracellular
mature virions and the extracellular virions, combined proteins from these viral forms can be used to better elicit a
complete and protective immunity.
Methods: Four novel viral recombinants were constructed based on the fowlpox genetic background, which
independently express the vaccinia virus L1 and A27 proteins present on the mature virions, and the A33 and B5
proteins present on the extracellular virions. The correct expression of the transgenes was determined by RT-PCR,
Western blotting, and immunofluorescence.
Results and conclusions: Using immunoprecipitation and Western blotting, the ability of the proteins expressed
by the four novel FPL1R, FPA27L, FPA33R and FPB5R recombinants to be recognized by VV-specific hyperimmune mouse
sera was demonstrated. By neutralisation assays, recombinant virus particles released by infected chick embryo
fibroblasts were shown not be recognised by hyperimmune sera. This thus demonstrates that the L1R, A27L, A33R
and B5R gene products are not inserted into the new viral progeny. Fowlpox virus replicates only in avian species,
but it is permissive for entry and transgene expression in mammalian cells, while being immunologically non–cross-
reactive with vaccinia virus. These recombinants might therefore represent safer and more promising immunogens
that can circumvent neutralisation by vector-generated immunity in smallpox-vaccine-experienced humans.
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Preventive vaccination still remains the most effective
control against orthopoxvirus (OPXV) infections, as it
can elicit neutralising antibodies against an incoming
virus. The traditional smallpox vaccine was administered
by scarification, but its use was discontinued in the gen-
eral population from 1980, because of the absence of
new smallpox cases. However, attenuated strains of vac-
cinia virus (VV) have been produced and tested in
humans in attempts to develop strains with lower reacto-
genicity and fewer side effects. Indeed, in spite of the dis-
continuation of the smallpox vaccination programmes,
the threat of deliberate release of variola virus for bioter-
rorism and the need for protection from new zoonotic in-
fections still remain [1-4]. Also, the monkeypox virus
(MPXV) resembles smallpox in the severity of its symp-
toms, and it might be a potential bioweapon if cowpox
and MPXV can adapt to grow and spread in humans [5].
VV recombinants that express different transgenes
have already been used in clinical studies for the preven-
tion and immunotherapy of different infectious diseases.
However, although extremely effective, VV raises safety
concerns due to its high reactogenicity, its ability to
spread to non-vaccinated subjects, and its moderate to se-
vere side effects [6], especially in immune-compromised
individuals [7]. Such side effects are not acceptable in a
post-endemic smallpox era [6,8]. Clinical trials have also
been performed with the attenuated VV-derived Lister
clone LC16m8 and the modified vaccinia Ankara (MVA).
LC16m8, which replicates in humans, showed protective
efficacy in animal models, and was safely used for over
50,000 children in Japan in 1974 [9]. MVA has an exten-
sive history of safety in humans, it is immunogenic and ef-
ficacious in both mice and non-human primates, where it
can also protect against MPXV, and it is a leading candi-
date for an alternative smallpox vaccine [10-13]. However,
as MVA replication in mammals is only partially abortive
[14], and induces lower immunogenicity than the trad-
itional smallpox vaccine [15], the search for new alterna-
tives is still ongoing [16,17]. Failure of protection with
MVA has been demonstrated in animals with CD4/CD8
combined immunodeficiency [6] and in Rhesus macaques
infected with simian immunodeficiency virus with a very
low cell count of the immune repertoire [18].
The VV antigens that protect against smallpox are not
completely known. However, analysis of the immune re-
sponses after immunisation with traditional vaccines has
shown that the neutralising antibodies are mainly di-
rected against the surface proteins of the two infectious
forms of OPXVs: the intracellular mature virions (MVs)
and the extracellular virions (EVs). MVs are released after
cell lysis, and they are responsible for the host-to-host
spread because of their stability in the extracellular envir-
onment. In contrast, EVs are wrapped by an additionalenvelope, and they have an important role in cell-to-cell
spread; i.e., in the dissemination within the host [19,20].
In particular, the L1 and A27 proteins on MVs and the
A33 and B5 proteins on EVs are involved in the attach-
ment, fusion and penetration of the virus into target cells
[20,21]. Combined DNA-based vaccines expressing these
four proteins are more protective than vaccines carrying
individual immunogens [22,23], possibly because of the in-
duction of synergistic antibodies that can act at the differ-
ent infection phases, both at the initial exposure, and
during viral dissemination [24,25].
Although other immunogens have been used to induce
protective immunity, when these four genes have been
delivered as DNA expression plasmids [22] or as virus-like
replicons [17], they have already been shown to induce
functional antibodies and to protect mice against VV
parenteral/ intranasal challenge, and monkeys against
MPXV intravenous challenge [26,27].
In the present study, four novel recombinants were
constructed based on the fowlpox (FP) genetic back-
ground that express the VV L1R, A27L, A33R and B5R
genes independently. Their correct expression was deter-
mined by RT-PCR, Western blotting and immunofluor-
escence, both in replication-permissive chick embryo
fibroblasts (CEFs) and in non-permissive mammalian
Vero and MRC-5 cells. The ability of the proteins
expressed by the four novel recombinants to be recog-
nized by VV-specific hyperimmune mouse sera was dem-
onstrated by immunoprecipitation followed by Western
blotting (IP/WB) using hyperimmune mouse serum. The
recognition by VV-specific antibodies of a mixture of the
four FP recombinants (4FPmix) was tested using a plaque-
reduction neutralisation assay.
FP vectors are replication-restricted to avian species
[28], but they are permissive for entry and transgene ex-
pression in mammalian cells, while being immunologically
non–cross-reactive with VV. They therefore represent
safer immunogens [29], as they can circumvent neutralisa-
tion by vector-generated immunity in smallpox-vaccine-
experienced humans. The advanced replication cycle, long
transgene expression, and balanced Th1/Th2 cytokine in-
duction of FP-based recombinants [28] might elicit a more
effective immune response.
Methods
Cells
Specific-pathogen-free primary CEFs were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 5% heat-inactivated calf serum (Gibco Life
Technologies, Grand Island, NY, USA), 5% Tryptose
Phosphate Broth (Difco Laboratories, Detroit, MI, USA),
100 U/ml penicillin and 100 mg/ml streptomycin. Green
monkey kidney (Vero) cells, and normal human lung
fibroblasts (MRC-5 cells) were grown in DMEM
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100 U/ml penicillin and 100 mg/ml streptomycin.
Construction of the recombinants
Four FP-based recombinants expressing the VV MV L1
and A27 proteins and the EV A33 and B5 proteins were
obtained by in-vitro homologous recombination [30-32],
with minor modifications. FPwt was obtained by J. Taylor
(Wadsworth Center, NY State Dept. of Health, Albany,
NY) [29]. Molecular cloning of pFPA33R and preparation
of the FPA33R recombinant have already been described
[33]. For FPL1R, FPA27L and FPB5R, these genes were PCR-
amplified from the Lancy strain of VV DNA (Berna
Biotech, courtesy of M. R. Capobianchi, L. Spallanzani
National Institute for Infectious Diseases, Rome, Italy).
They were separately inserted into the pcDNA3 and
pBSII plasmids (L1R), the pBSII plasmid (A27L), or the
pcDNA3 and pAFTd plasmids (B5R). Insertion into the
pFPMCS recombinant plasmid was performed downstream
of the VV H6 early/ late promoter [34], inside the 3-β
-hydroxysteroid dehydrogenase 5-delta 4 isomerase gene
interrupted by a multiple cloning site. The amplification
of L1R was carried out using the forward V182 (5’ GGG
AAG CTT TTA AAT GGG TGC CGC AGC AAG CAT
ACA 3’) and reverse V183 (5’ GGG CTC GAG ATT TTC
AGT TTT GCA TAT CCG TGG TAG 3’) primers. For
A27L, the forward V354 (5’ CCC GGG AAG CTT AAT
GGA CGG AAC TCT TTT C 3’) and reverse V353 (5’
TTT TGG TAC CAT AAA AAT TAC TCA TAT GGG
CGC CG 3’) primers were used. For B5R, the forward
V184 (5’ GGG AAG CTT AAA AAT GAA AAC GAT
TTC CGT TGT TAC 3’) and reverse V185 (5’ GGG CTC
GAG ATA TTT ACG GTA GCA ATT TAT GGA ACT
3’) primers were used. Amplifications were performed as
described previously [35], using 2.5 mM MgCl2 and 2 mM
MgSO4, with annealing at 61°C for 30 s (L1R and A27L),
or at 57°C for 30 s (B5R) and extension at 72°C for 45 s.
The β-actin reference gene was amplified using the for-
ward V84 (5’ CTG ACT ACC TCA TGA AGA TCC T 3’)
and reverse V85 (5’ GCT GAT CCA CAT CTG CTG
GAA 3’) primers, with 1 mM MgSO4 and with annealing
at 60°C for 30 s. The plasmid DNAs were purified and the
genes were sequenced (Genenco, MMedical, Milan, Italy),
to exclude any mutations arising from the PCR amplifica-
tion. The plasmids are designated as pFPL1R (8,992 bp),
pFPA27L (8,568 bp), pFPA33R (8,764 bp), and pFPB5R
(9,173 bp). Recombinants were obtained by in-vitro hom-
ologous recombination in CEFs, using FPwt and the dif-
ferent pFP recombinants, with minor modifications.
Recombinant plaques were identified by autoradiography
after hybridisation with [32P]-labelled specific probes, and
then subjected to multiple cycles of plaque purification.
One clone was selected for correct and high expression of
each gene by Western blotting, using specific antibodies.The recombinant viruses were amplified in CEFs, purified
on discontinuous sucrose density gradients, and titrated
essentially as already described [36]. Briefly, the cells were
harvested, ultracentrifuged at 30,000× g for 2 h at 4°C,
and the pellets resuspended in 1 mM Tris, 150 mM NaCl,
1 mM EDTA, pH 7.4. The pellet then had 0.06% trypsin
added, and was incubated for 5 min at 37°C, and the virus
was released from the cells by sonication. The supernatant
was overlaid onto a discontinuous 30% to 45% (w/w) su-
crose gradient, in the same buffer. After ultracentrifuga-
tion at 38,000× g for 1 h, the viral band at the interface
was recovered, diluted with 1 mM Tris-HCl, pH 9, and
pelletted at 67,000× g for 1 h. The purified virus was
resuspended in Ca++- and Mg++-free phosphate-buffered
saline (PBS-), disaggregated by sonication, aliquoted, and
frozen at -80°C until use.
RT-PCR
The expression of L1R, A27L, A33R and B5R was inves-
tigated by RT-PCR. The cells were infected with 1
plaque-forming unit (PFU)/cell of the FPL1R, FPA27L,
FPA33R or FPB5R recombinants, and the mRNAs were
extracted 24 h post-infection (p.i.) from CEFs and Vero
and MRC-5 cells, as described previously [28]. Briefly,
50 ng RNA from each sample was used in a final volume
of 10 μl, in the presence of 1 μM of each primer,
200 mM of each dNTP, 0.1 U/μl Thermus flavus DNA
polymerase, and 0.1 U/μl avian myeloblastosis virus re-
verse transcriptase, using the V182/V183 primers for
L1R (779 bp), V354/V353 for A27L (363 bp), V186/V187
for A33R (584 bp), V184/V185 for B5R (980 bp), and
V84/85 (518 bp) for β-actin detection under the condi-
tions described above. RNA from FPwt-infected cells
was used as a negative control. The RT-PCR products
were quantified using the ImageJ software [37].
Western blotting
To determine whether the L1, A27, A33, and B5 pro-
teins were expressed by the recombinants at the same
levels in the different cell lines, CEFs and Vero and MRC-
5 cells were infected (10 PFU/cell) and examined by
Western blotting, as already described [38]. The blotted
nitrocellulose membranes were incubated overnight at
4°C with 1:100 dilutions of the primary antibody. Alter-
natively, two different specific antibodies (Beiresources,
Manassas, VA, USA) were used for each gene: a mouse
monoclonal antibody followed by goat anti-mouse
horseradish-peroxidase-conjugated serum, and a rabbit
polyclonal antibody followed by goat anti-rabbit
horseradish-peroxidase-conjugated serum (1:2,000 dilu-
tion; DakoCytomation, Carpinteria, CA, USA). After a 1-h
incubation and 2 h of washes, the proteins were revealed
using the ECL system (EuroClone, Pero, Milan, Italy). Cells
infected with FPwt were used as the negative control.
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Conventional Western blotting was also performed after
immunoprecipitation of cell lysates using specific anti-
bodies (IP/WB). Vero cells were infected as for Western
blotting, and immunoprecipitation was performed essen-
tially as already described [35], with minor modifica-
tions. Sixteen hours p.i., the cells were harvested by
resuspension in 1 ml lysis buffer (150 mM NaCl, 1 mM
EDTA, 10 mM Tris-HCl, pH 7.4, 0.2 mg/ml PMSF, 1%
NP40, 0.01% sodium azide) per Petri dish, and 0.6 TIU
aprotinin (Sigma, St Louis, MO, USA). The lysate was
clarified by centrifugation at 9,000× g for 20 min at 4°C,
and immunoprecipitation was performed with 10 μl anti-
IHD-J mouse hyperimmune serum, from our laboratory.
The proteins were resolved using 15% SDS-PAGE, iden-
tified using a polyclonal antibody (Beiresources), and
revealed using the ECL system.
Immunofluorescence
Protein expression by the recombinant viruses was also
examined by immunofluorescence, which was carried
out in CEFs and Vero and MRC-5 cells, essentially as
described previously [35]. In particular, after infection at
37°C for 1 h with 1 or 3 PFU/cell (depending on the dif-
ferent cytopathogenicity of the recombinants), the cells
were grown for 6 or 15-18 h before immunofluores-
cence. The cells were fixed either with only fresh 2% para-
formaldehyde in PBS- for 10 min, for membrane
immunofluorescence, or with paraformaldehyde followed
by 100% cold acetone for 5 min at -20°C, for cytoplasmic
immunofluorescence. The samples were incubated for 1 h
with monoclonal or polyclonal antibodies (Beiresources)
(Table 1). FITC 1:100-diluted anti-mouse or anti-rabbit
secondary antibodies (Cappel, MP Biomedicals, Inc.,
Aurora, OH, USA) were used. Cells infected with FPwt
were the negative controls. The samples were viewed
under a Zeiss Axioskop epifluorescence microscope.
IHD-J and preparation of the four FP recombinants
mixture
The IHD-J strain of VV was kindly obtained from S. Dales
(University of Western Ontario, London, Canada) [39]
grown in Vero cells, and used to repeatedly infect
Balb/c mice (1 × 105 PFU/mouse) via the airways, toTable 1 Antibody dilutions for IF
FP recombinant MoAb PolyAb
FPL1R neg 1:50
FPA27L neg 1:50
FPA33R 1:50 1:50
FPB5R 1:20 1:200
MoAb, mouse monoclonal antibody.
PolyAb, rabbit polyclonal antibody.
neg, no positive IF at any dilution.obtain VV-specific hyperimmune serum. A mixture of the
four FP recombinants (4FPmix) was also prepared in
CEFs, by co-infection with the four FP viruses (3 PFU/
cell/each recombinant virus). The IHD-J and the 4FPmix
viruses were amplified in Vero cells and CEFs, respect-
ively, purified on discontinuous sucrose density gradients,
and titrated as already described.
Virus neutralisation assays
Recognition of the 4FPmix by VV-specific mouse anti-
bodies was tested using the virus neutralisation assay.
VV IHD-J hyperimmune mouse serum was used to de-
termine the inhibition of the infectivity of the 4FPmix.
Neutralisation assays were performed by pre-incubating
the 4FPmix with an equal volume of heat-inactivated
hyperimmune serum, for 1 h at 37°C. Pre-immune
serum was used as a negative control. The IHD-J virus
was used in a parallel test with both pre-immune and
hyperimmune serum. The sera were diluted starting
from a 1:20 dilution in DMEM. The viral inoculum was
adjusted to give approximately 102 PFU/Petri dish. Infec-
tion was allowed to proceed for 1 h at 37°C. The cells
then had 5 ml DMEM with agarose LE 0.7% (SeaKem,
FMC BioProducts, Rockland, ME, USA) added. The
plaque numbers were counted on day 4 p.i., after adding
an agarose layer containing 1.5% neutral red (Gibco).
The neutralisation is expressed as the percentage of re-
duction of plaque numbers versus the control, where the
viral inoculum was incubated with no serum.
Results
Transcript expression by the FP recombinants is similar in
the different cell lines
After RNA isolation from the infected CEFs and Vero
and MRC-5 cells, the transcripts were detected by RT-
PCR after an overnight incubation, as 779-bp, 363-bp,
584-bp and 980-bp fragments in all of the cell lines
infected by the FPL1R, FPA27L, FPA33R and FPB5R recom-
binants, respectively (Figure 1, lanes A). As determined
by densitometric analysis, similar levels of expression
were observed in the different cells for each recombin-
ant, except for FPB5R, that expressed the B5R mRNA 2.1
times more in human MRC-5 cells than in CEF and
Vero cells. The amplification of human β-actin RNA is
also shown as a 518-bp band (Figure 1, lanes A). As
expected, the FPwt-infected cells used as a negative con-
trol did not show any specific band (Figure 1, lanes B).
The recombinant proteins are expressed by all of the FP
recombinants in all of the different cell lines, although at
different levels
The FP recombinants expression was verified by West-
ern blotting on lysates of both replication-permissive
CEFs and non-permissive Vero and MRC-5 cells, which
a518
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A B
MRC-5
A B
Vero
A B
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Figure 1 Expression of the FPL1R, FPA27L, FPA33R and FPB5R
transcripts by RT-PCR in replication-permissive and non-
permissive cells. Following infection of CEFs and Vero and MRC-5
cells with the four recombinants, transcript expression was detected
after overnight infection, as 779-bp (panel a), 363-bp (panel b), 584-
bp (panel c) and 980-bp (panel d) fragments. Expression of human
β-actin is shown as a 518-bp band (panels a-d). No specific band is
seen for cells infected with FPwt, which was used as a negative
control (lanes B).
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FPB5R, or with FPwt. The polyclonal primary antibodies
recognised specific 27-kDa, 12.7-kDa, 21-kDa and 37-kDa
bands, which corresponded to the L1, A27, A33 and B5
proteins, respectively, in the infected CEFs and Vero and
MRC-5 cells (Figure 2, lanes B). As determined by densi-
tometric analysis, the expression levels for FPL1R were
4.2-fold and 3.9-fold higher in CEFs and Vero cells thanL1
A B
MRC-5
A B
Vero
A B
CEF
27
A33
A B
MRC-5
A B
Vero
A B
CEF
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MRC-5
A B
Vero
A B
CEF
12.7
kDa
B5
A B
MRC-5
A B
VeroCEF
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Figure 2 Transcript expression by Western blotting in
replication-permissive and non-permissive cell lines. All of the
different cell lines, the CEFs and Vero and MRC-5 cells, were infected
with 10 PFU/cell of FPL1R, FPA27L, FPA33R or FPB5R, and harvested
15-18 h p.i.. Rabbit polyclonal primary antibodies recognised the
corresponding proteins, in all of the cell lines (lanes B). The
expression levels were quantified by densitometric determinations.
No specific bands were seen when the cells were infected with
FPwt (lanes A).in MRC-5 cells, those for FPA27L were 2.9-fold and 2.5-fold
higher in CEFs and Vero cells than in MRC-5 cells, those
for FPA33R were 2.6-fold and 3-fold higher in CEFs and
MRC-5 cells than in Vero cells, and those for FPB5R were
2.1-fold and 3.1-fold higher in Vero and MRC-5 cells than
in CEFs (Figure 2; lanes B). No specific bands were
recognised when the cells were infected with FPwt
(Figure 2; lanes A). The corresponding monoclonal anti-
bodies showed similar specificity, but lower binding activ-
ity (data not shown).
Vaccinia hyperimmune mouse serum recognises
FP-expressed heterologous proteins
IP/WB was used to test whether the hyperimmune
mouse sera could also recognise the FP-expressed pro-
teins. After infection of the Vero cells with the FPL1R,
FPA27L, FPA33R and FPB5R recombinants, the specific pro-
teins were immunoprecipitated from cell lysates using
sera from mice that had been repeatedly immunised with
VV IDH-J (Figure 3, lanes B). No specific bands were seen
for cells infected with FPwt (Figure 3, lanes A).
Different localisation of the foreign proteins is detected
by immunofluorescence
To identify differences in the heterologous protein ex-
pression and subcellular localisation in the different cell
lines, immunofluorescence was performed at 15-18 h p.i.
in CEFs and Vero and MRC-5 cells infected with the
FPL1R, FPA27L, FPA33R and FPB5R recombinants, or with
FPwt (Figure 4). The cells infected with FPL1R and FPA27L
showed diffuse cytoplasmic fluorescence (Figure 4A, 1a-c,
2a-c), although the specific staining with FPL1R was only
slightly greater than the negative control, in all of the cell27 12.7
kDa kDaA B A B
L1 A27
21 37
A B A B
A33 B5
kDa kDa
Figure 3 Immunoprecipitation/Western blotting. To verify the
recognition of the FP-expressed proteins also by VV-specific
hyperimmune mouse sera, immunoprecipitation was performed,
followed by Western blotting. After infection with FPL1R, FPA27L,
FPA33R or FPB5R, the specific proteins were immunoprecipitated by
the hyperimmune sera (lanes B). No specific bands were seen in
cells infected with FPwt (lanes A).
Figure 4 Heterologous protein localisation by immunofluorescence. (A) Intracellular immunofluorescence was detected in all of the cell
lines, with differences between the proteins ascribed to MV or EV particles. In cells infected with FPL1R or FPA27L the cytoplasmic
immunofluorescence was diffuse (panels 1a-c, 2a-c), and in FPL1R-infected cells, the difference with the negative control was very low. Conversely,
specific, granular perinuclear localisation was shown by the cells infected with FPA33R or FPB5R (panels 3a-c, 4a-c), which was particularly evident in
MRC-5 cells infected with FPA33R. FPwt-infected cells were negative (panels 5a-c). (B) MRC-5 cells showed membrane immunofluorescence only
after infection with the FPA33R recombinant (panel 1b vs. 1a).
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perinuclear and cytoplasmic localisation in the cells
infected with FPA33R and FPB5R (Figure 4A, 3a-c, 4a-c),
which was particularly evident in the MRC-5 cells
infected with FPA33R. FPwt-infected cells were always
negative (Figure 4A, 5a-c). Immunofluorescence per-
formed at 6 h p.i. gave similar results (data not shown).
Membrane immunofluorescence was present only after
infection with the FPA33R recombinant in MRC-5 cells
(Figure 4B, 1b vs. 1a). Polyclonal and monoclonal anti-
bodies were used at different dilutions for the different
recombinants (Table 1).The 4FPmix is not neutralised by VV hyperimmune serum
To determine whether the FP recombinant virions pro-
duced by the CEFs were carrying the structural products
of the four transgenes on their surface, the 4FPmix,
containing a mixture of all of the FP recombinants, was
incubated with VV IHD-J hyperimmune serum. No re-
duction in plaque numbers was detected, as compared
to samples where pre-immune serum was incubated
with the IHD-J virus. High neutralising activity was seen
in samples where IHD-J was pre-incubated with IHD-J
hyperimmune serum (Figure 5).Discussion
Development of alternative replication-deficient vaccine
candidates against smallpox and other zoonotic OPXV
infections is still needed as a defence against new pox-
virus outbreaks as well as to reduce the adverse reac-
tions of traditional vaccines and the limited immune0
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Figure 5 Virus neutralisation assay. A mixture of all of the four FP
recombinants (4FPmix) was incubated with IHD-J hyperimmune
serum to determine whether the proteins expressed by the
recombinants were localised on the surface of the new viral
progeny. High neutralising activity was detected only in the samples
where IHD-J was pre-incubated with IHD-J-hyperimmune
mouse serum.responses in VV-experienced individuals. Along with
discontinuation of the smallpox vaccination campaign
and the decline in herd immunity in most countries, an
increase in MPXV infections has been described [40,41],
which has mostly occurred in children, young adults,
and immune-compromised patients [42]. MPXV is
widely distributed in a variety of African rodents, and
particularly in squirrels, which might be the reservoir
[43], and it has the potential to be used as a bio-weapon
[41,44,45]. Outbreaks of human MPXV infections were
also reported in the Unites States in 2003, with 69
people infected following the importation of MPXV-
infected rodents from West Africa. Also, in the Republic
of Congo in 1996-1997, there were 92 cases and 3 deaths
[46], which might have been related to the overall
vanishing immunity against poxviruses throughout the
world community.
The available smallpox vaccines based on VV show
relatively high rates of adverse side effects, and new
strategies should therefore be devised to improve the
safety of traditional smallpox vaccines. Replication-
deficient vaccines should reduce the risks for animal
handlers that arise from accidental exposure to
cowpoxvirus and other OPXV, limit the OPXV-infection
of domestic animals, and should be useful for protective
immunization in the event of intentional or accidental
release of variola virus.
In the present study, we have described the character-
isation of four new FP recombinants, FPL1R, FPA27L,
FPA33R and FPB5R, that express the VV L1R, A27L, A33R
and B5R genes. We demonstrated that: (i) all of these
recombinants can express the proteins correctly, al-
though at different levels in different cell lines, as re-
vealed by RT-PCR and Western blotting; (ii) MV and EV
proteins show different subcellular localisations; (iii) re-
combinant FP virions (4FPmix) are resistant to neutral-
isation by VV-specific serum; and (iv) the four FP
recombinants express functional foreign proteins that
are immunoprecipitated by hyperimmune serum from
IHD-J-immunised mice.
Using Western blotting, heterologous VV-specific pro-
teins were detected in cells infected by the four
recombinants. Their expression in human and non-
human primate cells was often higher than in CEFs,
where the virus replicates. This can be ascribed to the
cytocidal effect of the FP recombinants in avian cells, al-
though it is not clear why this occurs only for the ex-
pression of specific genes. In particular, the higher
transgene expression by FPB5R in human MRC-5 cells
confirms the results already shown by RT-PCR. IP/WB
was used to overcome the difficulty of revealing cell-
expressed antigens by conventional Western blotting, es-
pecially when using mouse or human hyperimmune
sera. This assay, which better avoids nonspecific binding
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able, showed that these proteins can be recognised by
VV-specific hyperimmune mouse serum.
By immunofluorescence, the heterologous proteins
were mainly localised at the cytoplasmic level for all of
the recombinants, and also at the membrane surface
when MRC-5 cells were infected with FPA33R. Although
no specific differences were observed among the cells
lines, the expression of the proteins belonging to MV
particles was always lower than the expression of the
proteins belonging to EV particles. In particular, the
intracellular expression of A33 and B5 was granular,
perinuclear and cytoplasmic, which confirms previously
reported data, and demonstrates their high expression in
the juxtanuclear area and Golgi region [47]. Membrane
fluorescence was only detectable after infection with
FPA33R. This also confirms previous data showing the
spontaneous translocation of the A33 protein to the
plasma membrane, which, using a FPB5R recombinant,
was only observed in very low amounts by immuno-
electron microscopy, but not by immunfluorescence
[47]. The very low fluorescence detected after FPL1R infec-
tion can either be ascribed to limited protein expression,
which was not confirmed by the Western blotting, or to
the low avidity of the antibody. This is also confirmed by
other studies, where low expression was overcome by the
use of the phorbol ester 12-O-tetradecanoylphorbol-13-
acetate (TPA) [48].
The absence of neutralising activity of IHD-J-specific
hyperimmune mice sera against the virus particles re-
leased by CEFs infected with the four FP recombinants
suggests that the L1, A27, A33 and B5 gene products
may not be inserted into the envelope of the new viral
progeny. This enhances the importance of these FP
recombinants for their use in individuals who have
already been vaccinated against smallpox, where these
can be administered as a recall. As human peripheral
blood monocytic cells and macrophages are permissive
for penetration of the recombinants and expression of
foreign proteins [28], antigen cross-presentation should
occur, which should result in complete humoral and cel-
lular immune responses.
Conclusions
To avoid lytic infection, ulceration and scab formation
after dermal scarification with VV for smallpox prophy-
laxis, FP recombinants represent alternative safer immu-
nogens. This arises from their natural host-range
restricted replication to avian species [49], their correct
transgene expression in mammalian cells, and their abil-
ity to elicit a complete immune response in vaccinated
hosts [50]. Although these L1R, A27L, A33R and B5R
VV-derived genes have already been successfully
expressed using recombinant DNA [22,48], the use ofavipox recombinants expressing these genes might pro-
vide better control against zoonotic OPXV infections,
will offer advances in the fight against the threat of bio-
terrorism, and can also be used in VV-experienced
individuals.
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